Atrial fibrillation (AF) is the most common cardiac arrhythmia, and is a cause of significant morbidity and mortality if left untreated. AF has been associated with profound changes in sarcoplasmic reticulum Ca 2+ homeostasis, which might contribute to both reduced contractile function and increased arrhythmogenesis in atria. Studies in human tissue samples and various animal models of AF have revealed changes in both expression levels and posttranslational modifications of key Ca 2+ handling proteins, which may contribute to arrhythmogenesis. In this review, we will focus on the molecular basis of alterations in sarcoplasmic reticulum Ca 2+ handling in AF and their potential therapeutic implications.
Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with a lifetime risk of 20-25% [1] . The major cause of morbidity is thromboembolism leading to stroke, which arises from stasis of blood in atria due to decreased atrial contractility. Impaired intracellular Ca 2+ handling is believed to underlie atrial mechanical dysfunction [2] . The smaller amplitude of systolic Ca 2+ transient is a major determinant of decreased contractility in AF [3] . On the other hand, the predisposition to spontaneous diastolic sarcoplasmic reticulum (SR) Ca 2+ releases might contribute to arrhythmogenesis in AF by promoting triggered activity [4] . In this review, we will review the cellular and molecular basis of abnormal SR Ca 2+ handling in AF, and discuss how new drug therapies might be developed to reverse these defects.
Excitation-contraction coupling in atrial myocytes
Excitation-contraction coupling (ECC) is the fundamental process by which an action potential initiates contraction of a cardiomyocyte [5] . Plasma membrane depolarization leads to the influx of Ca 2+ via voltage-gated L-type Ca 2+ channels, which in turn triggers a much greater release of Ca 2+ from the SR via ryanodine receptor type 2 (RyR2) channels ( Figure  1 ). The ensuing systolic Ca 2+ transient leads to binding of Ca 2+ to troponin C, which induces a conformational change in the regulatory complex eventually leading to sliding of actin and myosin filaments past each other thereby shortening the sarcomere. During diastole, Ca 2+ is sequestered into the SR by sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA2a), reducing cytosolic Ca 2+ concentrations and facilitating myocyte relaxation [6] . To a smaller extent, Ca 2+ is also removed from the cytosol through the forward mode of the Na + /Ca 2+ -exchanger (NCX). The extent of re-loading of the SR with Ca 2+ critically determines the amplitude of the subsequent Ca 2+ transient and myocyte contractility. SR Ca 2+ release and reuptake during the excitation-contraction coupling cycle. The amplitude of the L-type Ca 2+ current (I Ca,L ) is enhanced by phosphorylation by protein kinase A (PKA), which is activated by stimulation of β-adrenoceptors on the plasmalemma [7] . PKA also phosphorylates RyR2 and SERCA2a-inhibitor phospholamban (PLN), thereby enhancing the release from and reuptake of Ca 2+ into the SR, respectively. In addition, Ca 2+ / calmodulin-dependent kinase II (CaMKII) has been shown to increase RyR2-mediated SR Ca 2+ release and to relieve the effects of PLN inhibition on SERCA2a activity [8, 9] . Thus, several intracellular signaling pathways involving protein phosphorylation of Ca 2+ channels and transporters dynamically modulate excitation-contraction coupling to maintain homeostasis.
There are important differences in the subcellular architecture of atrial and ventricular cardiomyocyte Ca 2+ release units that provide the structural framework for intracellular Ca 2+ release and reuptake associated with excitation-contraction coupling. For example, the Ca 2+ transient is smaller and spatially more dispersed in rat atrial myocytes compared with ventricular myocytes [10] . In rat atrial cells, systolic Ca 2+ transients arise at cell periphery and then propagate as waves into the cell interior presumably due to the relative absence of transverse T-tubules [11] . Reuptake of Ca 2+ into the SR is more robust in atrial myocytes, and SR Ca 2+ content is relatively greater compared with ventricular myocytes. Whereas the enhanced SR Ca 2+ load might facilitate arrhythmogenesis in pathologically remodeled atria, spontaneous Ca 2+ release does not occur in healthy atria. Please refer to Dobrev [12] for a detailed review of Ca 2+ signaling features unique to atrial myocytes.
Regulation of SR Ca 2+ release in the atria
As in ventricular myocytes, RyR2 are the principal Ca 2+ release channels responsible for Ca 2+ -induced Ca 2+ release (CICR) in atrial myocytes. The simultaneous opening of a group of RyR2 leads to Ca 2+ sparks, which are elementary SR Ca 2+ release events that can be visualized using confocal microscopy [13] . Many individual sparks coalesce to give a characteristic Ca 2+ wave that initiates the global Ca 2+ transient associated with myocyte contractility [14] .
A unique property of atrial myocytes is that inositol 1,4,5-trisphosphate receptors (IP 3 R) are located close to RyR2 in the subsarcolemmal space [15] . It is believed that IP 3 R can increase local Ca 2+ concentrations in the vicinity of RyR2, thereby facilitating CICR during excitation-contraction coupling [16] . Expression levels of IP 3 R are about 5-10 times higher in rabbit atrial compared to ventricular myocytes [17] . Consistent with this observation direct application of IP 3 to permeabilized rat atrial myocytes evoked a 5-times larger global Ca 2+ transient compared to ventricular cells [15] . Ca 2+ release via RyR2 is also regulated by accessory subunits that bind directly to the RyR2 macromolecular complex [18] . Whereas most initial studies on the composition of the RyR2 protein complex were performed on ventricular myocardium, several recent studies suggest that atrial RyR2 are comprised of the same subunits and binding partners [19] [20] [21] [22] [23] . RyR2 are tetramers comprised of four RyR2 subunits, each of which associates with several regulatory subunits. Calmodulin (CaM) is an accessory protein that binds to and regulates RyR2 gating [24] . The FK506-binding protein (FKBP12.6, also known as calstabin2) stabilizes the RyR2 closed conformational state [20, 25] , and facilitates coupled gating between connected RyR2 channels [26] . Marx et al. [18] demonstrated that protein kinase A (PKA) and protein phosphatases PP1 and PP2A bind to RyR2 via specific targeting molecules. These same proteins are present in the atrial RyR2 complex [21] . It has also been shown that atrial RyR2 are substrate of both PKA and CaMKII-mediated phosphorylation. PKA phosphorylation of RyR2 at its main phosphorylation site S2808 increases RyR2 open probability [25, 27] .
More recent studies using recombinant RyR2 also demonstrated that PKA can also phosphorylate S2030, but the functional implications of this phosphorylation event remain unclear [28] . The enzyme Ca 2+ /calmodulin-dependent kinase II (CaMKII), on the other hand, phosphorylates S2814 [8, 19] . CaMKII phosphorylation of S2814 increases the sensitivity to Ca 2+ -induced activation and increases RyR2 open probability. Taken together, the atrial RyR2/ Ca 2+ release channel gating properties appear to be similar to those of RyR2 in the ventricle [29] . Additional proteins that bind to the luminal side of RyR2 include junctin and triadin [30] . Finally, RyR2 function is also regulated by the intra-SR Ca 2+buffering protein calsequestrin (CASQ2) [31] . The significance of these latter interactions remains to be established in the atria.
Regulation of Ca 2+ removal mechanisms in the atria
Compared to ventricular myocytes, SR Ca 2+ reuptake is enhanced in rat atrial myocytes, in part due to higher expression levels of SERCA2a [10] . In addition, levels of PLN are lower than in the ventricle [10, 32] . Because the SERCA2a/PLN ratio is about 4-times higher in atria, SR Ca 2+ reuptake is enhanced and relaxation of atrial myocardium is facilitated. In the atria, SERCA2a is also regulated by sarcolipin (SLN) [33] . Whereas SLN is predominantly expressed in the atria, PLN expression is more abundant in mouse ventricles [34] . SLN shares a 30% homology with the transmembrane domain of PLN, and its structure and function are very similar to this PLN domain [35] . SLN inhibits SERCA2a activity by decreasing the apparent Ca 2+ affinity of the pump [36] , a process that is dynamically regulated by phosphorylation. Similar to PLN, stimulation of β-adrenoceptors phosphorylates SLN at T5 and enhances contractility by decreasing SERCA2a inhibition [37] . Thus, SLN plays an important regulatory role in the atria.
It has been reported that, in the human atria, levels of Na + /Ca 2+ -exchanger (NCX) are about half of those found in the ventricle [38] . Lower NCX levels result in smaller NCX currents compared to ventricular cells [10] . However, atrial myocytes are smaller than ventricular myocytes and when the NCX current amplitude was corrected for cell size, rat atrial cells were found to have larger NCX current density compared to ventricular cells [10] . Thus, remodeling-related increases in SR Ca 2+ leak together with elevated NCX expression levels may generate large depolarising I NCX currents that may cause delayed afterdepolarisations and triggered activity, supporting AF maintenance (see below). Atrial myocytes exhibit markedly increased SR Ca 2+ content and cellular Ca 2+ buffering capacity [10] , consistent with enhanced SR Ca 2+ reuptake via SERCA2a. In addition, the Ca 2+ efflux via sarcolemmal pathways including NCX is reduced in atrial cells, and Ca 2+ entry via L-type Ca 2+ channels is increased. It has been also suggested that changes in myofilament properties may contribute to enhanced Ca 2+ buffering properties of atrial myocytes [39] . As discussed below, the greater SR Ca 2+ content in atrial cells may facilitate arrhythmogenenic spontaneous SR Ca 2+ releases in fibrillating atria.
Cellular and molecular mechanisms underlying of atrial fibrillation
Two major mechanisms believed to cause AF at the organ level include reentry and ectopic activity. Sources of these abnormalities are often localized at one of the pulmonary veins or in the posterior wall of the left atrium near the pulmonary vein junction [40] . Risk factors (i.e., age) and cardiovascular diseases (i.e., heart failure) increase the susceptibility to AF by causing specific electrical and structural substrates that promote arrhythmia maintenance once AF has been induced. Cardiovascular diseases can also contribute to the triggers (i.e. acute atrial dilatation) that initiate AF. Thus, the structural substrate caused by risk factors and concomitant disease conditions preceding AF is key for perpetuation of AF [41] .
Reentry requires a susceptible substrate as well as a trigger, usually provided by an ectopic beat. According to the "Leading Circle" concept, reentry results from a balance between tissue refractoriness and conduction speed [42] . Short refractoriness and slow conduction make induction of continuous conduction in a reentry zone more likely. According to the "Spiral Wave" concept [43, 44] , reentry is maintained by high-frequency reentrant sources (rotors) with a spiral wave rotating around a central "core". The stability of the rotor is determined by the tissue excitability and refractoriness: higher excitability and shorter refractoriness allow the spiral wave to rotate faster, stabilizing the rotor.
Ectopic activity may contribute to AF initiation by acting as a trigger of reentry. Ectopic activity is caused by abnormal local spontaneous discharges that can be due to afterdepolarizations. Afterdepolarizations are oscillations of the membrane potential of an atrial myocyte that occur during repolarization (early afterdepolarizations, EADs) or following completion of the action potential (delayed afterdepolarizations, DADs). Left atrial sources of ectopic activity appear to be of particular importance in a subset of patients with paroxysmal AF [45] .
EADs occur when an abnormal depolarization starts during phase 2 or 3 of the preceding action potential, and are commonly associated with bradycardia or pauses [46] . Pulmonary veins are a preferred site for EADs in canine atria [47] . Excessive action potential prolongations with re-activation of the L-type Ca 2+ current or late Na + current predispose to the development of EADs in isolated canine right atria [46] . EADs can also occur in the absence of intracellular Ca 2+ -handling abnormalities. Recently, 'late phase 3′ EADs were suggested to contribute to AF reinitiation [46] . This type of EADs may occur under sympathovagal discharges, if acetylcholine-induced action potential duration abbreviation (parasympathetic effect) is coupled with increased Ca 2+ transients (sympathetic effect; "Ca 2+ -transient triggering") [48] . It was postulated that this mechanism involves an increase in intracellular Ca 2+ concentrations during final action potential repolarization, at voltages negative to the equilibrium potential for NCX. These changes are presumed to increase inward NCX current to generate EADs and triggered activity [47, 49] .
DADs result from spontaneous diastolic SR Ca 2+ releases, typically caused by either SR Ca 2+ overload or dysfunction of the SR Ca 2+ release channels. They manifest as individual or series of small-amplitude membrane oscillations that could eventually lead to full-blown action potentials. The spontaneous SR Ca 2+ releases activate a transient inward current (I ti ), which underlies the DAD voltage oscillation [5, 50] . The occurrence of DADs has been demonstrated in multicellular preparations from isolated diseased human atrial appendages [51] . Electrical remodeling increases the likelihood of DADs during AF as discussed below.
Altered SR Ca 2+ handling in atrial fibrillation
It is well recognized that AF is a progressive disease, and that the arrhythmia itself induces electrical remodeling that increases susceptibility and stability of AF [52] . Several factors contribute to electrical remodeling, including shortening of the atrial effective refractory period, which is primarily caused by action potential shortening [53, 54] . At the cellular level, there are profound alterations in the mRNA and protein expression levels of various ion channels (for review, see Dobrev et al. [55] ) ( Figure 2 ). Besides reduced I Ca,L [56, 57] , increased function of inward rectifier K + currents may play a critical role as they abbreviate effective refractory period and hyperpolarize the resting membrane potential [58, 59] , thereby increasing Na + channel availability (and thus excitability) and enhancing rotor frequency [60] . Whereas some of these molecular and cellular alterations are well documented in humans and/or animals with AF, it often remains unknown whether these changes are a cause of AF or a consequence of the chronic atrial arrhythmia. AF-associated changes in proteins involved in intracellular Ca 2+ release and reuptake are reviewed below.
Structural remodeling of the atria also plays an important role in the susceptibility to atrial arrhythmias. The presence of areas of slow conduction or block may cause spatial dissociation of wavelets and promote reentry [42] . Atrial dilatation also increases the likelihood of AF due to increased heterogeneity of conduction [61] . The increase in atrial size is often associated with depressed atrial contractility, and together these changes increase the risk for thromboembolic complications [62] .
Multiple studies have shown that abnormal SR Ca 2+ handling plays a central role in the initiation and/or maintenance of AF in humans [21, 55] . Defective Ca 2+ handling, which may facilitate reentry and contribute to triggered activity, was shown to lead to an increase in spontaneous Ca 2+ release events from the SR in atrial myocytes isolated from patients in chronic AF [4] . Unexpectedly, SR Ca 2+ load was not increased in atrial myocytes from patients in AF [4] , suggesting that the spontaneous SR Ca 2+ releases most likely occurred because of alterations in RyR2. In contrast, Liang et al. [63] found that the frequency and amplitude of Ca 2+ sparks were comparable in human atrial myocytes of patients in sinus rhythm and in AF. However, the frequency of small and global Ca 2+ waves increased in atrial myocytes of AF patients. The authors suggested that the spatiotemporal properties but not the frequency of Ca 2+ sparks were affected in atrial myocytes from patients in AF. These findings and results from animal models point to abnormal SR Ca 2+ function in AF. Abnormal SR Ca 2+ release can act as a local trigger generator, initiating a local reentry circuit or ectopic focal activity in sheep atria [64] .
Downregulation of L-type Ca 2+ channel
Most studies in atrial myocytes isolated from patients in chronic AF have demonstrated a reduction of I Ca,L [56, 57] . A reduced I Ca,L current results in shortening of both the action potential duration and effective refractory period, which can promote AF maintenance [65] . In addition, reduced I Ca,L contributes to depressed atrial contractility by decreasing CICR from the SR [66] .
At the molecular level, inconsistent results have been reported about mRNA expression of the Cav1.2 subunit of I Ca,L in a variety of animal models and human tissue studies. Some investigations revealed decreased expression of Cav1.2 [67, 68] , α2/δ1 [69] , β1(b) [69] and α1d [68] , whereas other studies showed unchanged Cav1.2 [70] , β1(a,c) [69] or β2a subunit expression of I Ca,L [57, 66] . Several factors might explain these discrepancies, including species differences and time-dependent changes in remodeling in animal models. A recent study in mice lacking the Cav1.2 subunit of I Ca,L demonstrated an increased vulnerability to AF, suggesting that a reduction of I Ca,L may be causally linked to AF pathogenesis [71] .
In addition, it has been shown that abnormal posttranslational regulation of I Ca,L might contribute to AF. The I Ca,L subunits are phosphorylated by CaMKII [72, 73] and dephosphorylated by PP1 and PP2A. The increase of protein phosphatase activity in humans with AF [23, 57, 70] may overcome the enhanced CaMKII activity in AF, reducing I Ca,L amplitude [57, 73] . These results suggest that imbalances in kinase/ phosphatase signaling may contribute to the reduction of I Ca,L in patients with chronic AF. Whereas these findings might explain the reduced contractility in AF, they do not explain the increased incidence of spontaneous Ca 2+ release events from the SR.
Enhanced RyR2 activity in AF
As mentioned above, there is ample evidence for defective SR Ca 2+ handling in AF. Whereas reduced systolic SR Ca 2+ release can be attributed to downregulation of the I Ca,L current, other mechanisms are likely responsible for the paradoxal increase in diastolic nonevoked SR Ca 2+ release events [4] . Single channel recordings revealed an increased open probability of RyR2 isolated from dogs in chronic AF [21] . It is likely that enhanced RyR2 activity plays a role in AF pathogenesis, as mice with a gain-of-function mutation in RyR2 exhibit an increased susceptibility to pacing-induced AF [19] . Using these knock-in mice, it was demonstrated that increased SR Ca 2+ leak in atrial myocytes can promote triggered activity and atrial arrhythmias.
Expression levels of RyR2 were found to be unaltered [74, 75] or reduced in dogs and patients with chronic AF [76] [77] [78] . However, and perhaps more importantly, the binding levels of accessory subunits and posttranslational modification were altered in chronic AF in humans [21, 23] . For example, the level of the RyR2-stabilizing subunit FK506-binding protein (FKBP12.6, calstabin2) was reduced by about 50% in patients with chronic AF, which could explain why RyR2 channels fail to remain closed during diastole [21] . Interestingly, mice deficient in FKBP12.6 exhibit an increased vulnerability to pacinginduced AF and enhanced spontaneous SR Ca 2+ leak [20] . Reduced CSQ2 levels may also contribute to SR dysfunction in AF [78] .
Changes in the phosphorylation level of RyR2 have been reported consistently in chronic AF. Vest et al. [21] demonstrated increased PKA phosphorylation of S2808 on RyR2 in dogs with chronic pacing-induced AF and patients with chronic AF. Although total protein phosphatase levels and activity of PP1 and PP2A are increased in atria of patients in chronic AF, it is still unclear what happens to PP1 and PP2A levels within the RyR2 macromolecular complex [23] . PP1 is regulated by inhibitor-1 (I-1) and inhibitor 2 (I-2) [79] . El-Armouche et al. [23] demonstrated that the levels of I-1 and I-2 were not altered in patients with AF, but that I-1 phosphorylation at T35 was increased, which should lead to a strong inhibition of PP1 within the SR compartment, possibly contributing to enhanced RyR2 phosphorylation [80] .
RyR2 is also more phosphorylated by CaMKII at S2814 in human atrial samples from patients in chronic AF [19, 81] . It was shown that enhanced CaMKII activity and CaMKII phosphorylation of RyR2 lead to an increased propensity to diastolic SR Ca 2+ leak and atrial arrhythmias. Goats with sustained AF also show enhanced autophosphorylation and thus activity of CaMKII along with increased CaMKII-dependent RyR2 phosphorylation [22] , clearly suggesting that the high atrial rate is sufficient to cause these alterations. Notably, goats with atrial dilatation, but absence of sustained AF, also exhibit increased CaMKII activity and CaMKII-dependent RyR2 phosphorylation [22] , pointing to the possibility that structural atrial diseases may predispose to AF by producing changes in cellular Ca 2+ signaling. Indeed, genetic and pharmacological inhibition of CaMKII phosphorylation of RyR2 reduced the inducibility of AF in mice, suggesting that hyperphosphorylation of the RyR2 at S2814 might play a central role in AF pathogenesis [19] . The absence of carbacholinduced AF in RyR2-S2814A knock-in mice, in which RyR2 phosphorylation by CaMKII was genetically inhibited, confirms the importance of this single phosphorylation event in the pathogenesis of atrial arrhythmias [19] .
Diastolic Ca 2+ leak persistence is promoted only if normal or enhanced SR Ca 2+ load can be maintained [97] . In AF patients, PLN is hyperphosphorylated at both serine 16 (PKA site) and threonine 17 (CaMKII site), respectively, and this may prevent SR Ca 2+ depletion in AF, explaining the preserved SR Ca 2+ content [4, 23, 81, 82] . Dogs with experimental heart failure show increased SR Ca 2+ load, along with enhanced CaMKII phosphorylation of PLN and increased frequency of delayed afterdepolarisation events in atrial cells [78] . These data and the results discussed above suggest that part of the changes detected in patients with chronic AF might result from structural changes of the atria, heart failure and other risk factors and clinical conditions. Further extensive work in suitable patient populations and experimental models is needed to dissect the specific contributions of the preceding cardiac pathologies to the promotion of AF.
Enhanced IP 3 R activity in AF
Yamda et al. [83] demonstrated an upregulated expression of IP 3 R in atrial tissue samples from patients with chronic AF. Other studies have confirmed this in human atrial tissue [84] and a canine model of rapid atrial pacing [77] . Since activation of IP 3 R increases the frequency of spontaneous Ca 2+ sparks [85] , Ca 2+ waves [86] , and arrhythmogenic contractions [87] , it is likely that the additional presence of IP 3 R contributes to spontaneous Ca 2+ release events from the SR [88, 89] . Activation of IP 3 R facilitates the generation of EADs and DADs in atrial myocytes, and these effects can be counteracted by an IP 3 R blocker such as aminoethoxydiphenyl borate (2-APB) [90, 91] . In addition, a causal link between IP 3 R and arrhythmias was demonstrated in IP 3 R2-deficient mice, as endothelin failed to induce arrhythmogenic spontaneous Ca 2+ release events in the knockout mice [92] . Thus, upregulation of IP 3 R may play a role in enhancing SR Ca 2+ release defects in AF. Further studies are clearly required to elucidate the complex interplay of IP 3 R and RyR2 in the pathogenesis of AF.
Reduced SR Ca 2+ reuptake
The levels of SERCA2a are slightly downregulated by about 25% in patients with chronic AF [23] . On the other hand, several reports have demonstrated that mRNA and protein expression levels of PLN are unaltered in patients with chronic AF [23, [93] [94] [95] . However, there is evidence that both PKA and CaMKII-mediated phosphorylation of PLN are increased in patients in chronic AF [23] . Interestingly, elevated PLN phosphorylation occurs despite globally increased activity levels of PP1 and PP2A [23] , which highlights the importance of local differences in protein phosphatase activity and/or targeting within different microdomains in atrial myocytes.
In addition, it has been demonstrated that the expression of SLN is decreased in chronic AF in humans [95] . Together with the changes in PLN regulation, reduced SLN binding to SERCA2a could be expected theoretically to enhance SR Ca 2+ reuptake, which may offset the Ca 2+ loss due to increased SR Ca 2+ leak, potentially explaining the preserved SR Ca 2+ content in patients with chronic AF [4] . A recent genetic association study has suggested that some single nucleotide polymorphisms (SNPs) in the SLN gene might be associated with AF [96] .
Upregulation of NCX function in AF
Expression levels of NCX are upregulated in patients and goats with chronic AF [23, 93] . Despite potentially increased reverse-mode activity of NCX, contractile function is typically decreased in chronic AF, which could possibly be attributed to reduced I Ca,L in combination with increased myofibrillar Ca 2+ sensitivity and impaired atrial relaxation [23, 93] . On the other hand, if sufficient SR Ca 2+ is released into the cytosol during diastole, the greater abundance of NCX protein may result in a larger NCX inward current (forward-mode action) for a given Ca 2+ release, possibly promoting the occurrence of DADs and triggered activity that may contribute to AF maintenance.
Taken together, there is emerging evidence that altered cellular Ca 2+ signaling in the atria may contribute to both reentry and triggered activity, thereby promoting AF maintenance. However, there are important gaps in our knowledge about impaired atrial Ca 2+ handling. For instance, persistence of diastolic Ca 2+ leak requires maintained SR Ca 2+ load [97] . Although preliminary results in AF patients point to preserved global SR Ca 2+ load and enhanced functional NCX [82] , it remains to be determined whether increased SR Ca 2+ leak and sufficient SR Ca 2+ load occur at the subsarcolemmal SR compartment. The current evidence of increased SR Ca 2+ leak in AF patients is indirect [19, 21, 81] . Precise quantification of SR Ca 2+ leak in atrial myocytes from AF patients in combination with single channel recordings of RyR2 properties are clearly required. The quantitative relation between SR Ca 2+ leak, probability of occurrence of diastolic Ca 2+ waves and amplitude of NCX is currently unknown and it remains to be determined whether the size of the NCX current associated with SR Ca 2+ leak is sufficient to depolarize the membrane to the threshold needed for triggering an action potential. In addition, future work should also address the time course of reversibility of SR Ca 2+ abnormalities. Finally, although Ca 2+dependent focal sources are suggested to contribute to maintenance of clinical AF [98] , direct experimental evidence of the causal relationship between Ca 2+ -related cellular proarrhythmic events and focal sources in fibrillating human atria is still lacking.
Novel therapeutic approaches targeting abnormal SR function in AF
Traditionally, AF has been treated pharmacologically using drugs that block voltage-gated ion channels. Most of these agents, however, are also characterized by a profound proarrhythmogenic potential, which strongly limits their clinical applicability. New therapeutic strategies have emerged during the past 5 years as a result of a better understanding of the molecular pathways involved in atrial arrrhythmogenesis (reviewed in [99] ). It was suggested that the commonly used AF drug amiodarone might prevent atrial arrhythmias, at least in part, by preventing the AF-related downregulation of I CaL and thus electrical remodeling [100] .
New therapeutic modalities may include compounds that inhibit spontaneous SR Ca 2+ leak by normalizing the function of the RyR2 macromolecular complex (reviewed in Santonastasi et al. [5] ). The 1,4-benzothiazepine JTV519 (K201) has been shown to prevent AF in a canine model of sterile pericarditis [101] . JTV519 was also shown to reduce RyR2mediated SR Ca 2+ leak in mice by reversing disease-associated loss of FKBP12.6 binding to RyR2 [21, 102, 103] . Lehnart et al. [50] demonstrated in mouse ventricular myocytes that JTV519 could block spontaneous SR Ca 2+ releases and DADs that arise as a consequence of the SR Ca 2+ leak. In another study, JTV519 reduced firing rates in rabbit pulmonary vein cardiomyocytes, decreased amplitude of DADs, prolonged APD and reduced incidence of provoked AF [104] .
Other drugs may have similar effects on RyR2. For example, tetracaine was able to completely suppress Ca 2+ sparks in atrial myocytes from patients in chronic AF [63] . The type 1C anti-arrhythmic drug flecainide, better known for its Na + channel blocking effects, was shown to effectively inhibit arrhythmias induced by SR Ca 2+ leak in mouse myocytes [105] . Hilliard et al. [106] demonstrated that flecainide inhibits SR Ca 2+ leak by blocking RyR2 in the open state. Flecainide was also shown to inhibit intracellular Ca 2+ waves, probably due to a combined effect on RyR2 gating and voltage-gated Na + channels [106, 107] .
Dantrolene, a drug generally used to treat malignant hyperthermia, effectively prevents abnormal Ca 2+ release via type 1 RyR2 in skeletal muscle. Kobayashi et al. [108] recently demonstrated that dantrolene may also inhibit spontaneous SR Ca 2+ leak in the heart. Therefore, dantrolene or its derivatives may also be promising therapeutic agents for the treatment of cardiac arrhythmias, including AF. In addition to direct inhibition of RyR2, SR Ca 2+ leak may also be reduced by suppressing the activity of CaMKII in the atrium. Chelu et al. [19] demonstrated that pharmacological inhibition of CaMKII could inhibit the induction of AF in mice by reducing SR Ca 2+ leak.
Inhibition of Ca 2+ influx via reverse-mode NCX (Ca 2+ influx) might decrease Ca 2+ overload and halt the progression of the remodeling process. The NCX inhibitor KB-R7943 prevents short-term electrical remodeling-induced APD shortening in dogs [109] and prevents DADs and triggered activity in rabbit pulmonary veins [110] . Blockade of forward mode NCX (Ca 2+ efflux) should suppress DADs and triggered activity, but is expected to worsen Ca 2+ overload. Although NCX inhibitors like KB-R7943 are suggested to block NCX more efficiently in the reverse (Ca 2+ influx) than forward (Ca 2+ efflux) mode [111] , KB-R7943 is not selective and blocks L-type Ca 2+ channels [112] and transient receptor potential channels [113] . Compounds specifically reducing forward-mode NCX without interference with other key ion channels and transporters may prove efficient for AF treatment.
Conclusions and future perspectives
There is emerging evidence from animal models and human studies that abnormal Ca 2+ handling by the sarcoplasmic reticulum plays an important role in AF. Reduced I Ca,L current may be key to contractile dysfunction in AF. On the other hand, an increased incidence of spontaneous diastolic SR Ca 2+ release events might contribute to both the induction and maintenance of AF. Increased PKA and CaMKII phosphorylation of RyR2, and reduced binding of the FKBP12.6 subunit to RyR2, might evoke triggered activity [21, 114] . Relatively increased SERCA2a function due to alterations in PLN phosphorylation and SLN expression may enhance SR Ca 2+ reuptake, compensating for the RyR2-mediated diastolic SR Ca 2+ leak. Recent work in genetically-modified mice have provided important insights into the causal relationships between molecular alterations of single molecules in the context of AF susceptibility. However, it remains to be established whether cellular Ca 2+ -related proarrhythmic events are the underlying mechanism of atrial arrhythmogenic foci in patients in vivo. Nevetheless, new pharmacological agents are being developed to inhibit potentially arrhythmogenic diastolic SR Ca 2+ leak. These drugs might offer unique therapeutic advantages as they could improve atrial contractility and may reduce atrial arrhythmogenesis by normalizing SR Ca 2+ handling.
Figure 1. Schematic representation of excitation-contraction coupling in an atrial myocyte
With the advent of action potential, L-type Ca 2+ channels (LTCC) are activated resulting in influx of Ca 2+ . This influx of Ca 2+ activates the adjacent ryanodine receptors (RyR2) resulting in outpouring of Ca 2+ stored in sarcoplasmic reticulum (SR) into cytosol. IP 3 R are also activated alongside RyR2, and have a role in both inducing independent SR Ca 2+ release and amplifying SR Ca 2+ release through RyR2. The release of Ca 2+ activates the contractile proteins initiating systole. The increased cytosolic Ca 2+ inactivates LTCC, activates NCX (causing efflux of Ca 2+ ), and activates SERCA2a (causing reuptake of Ca 2+ into SR). This results in termination of systole and onset of diastolic phase. 
